Nat Commun:新研究确认110个基因与乳腺癌风险相关

2018-03-19 佚名 新华社

乳腺癌是女性最高发的癌症,预估风险对提高乳腺癌患者的存活率关系重大。英国研究人员最近通过一种新的测序技术发现了110个与乳腺癌风险有关的基因,可望为通过基因检测来预估乳腺癌风险铺平道路。

乳腺癌是女性最高发的癌症,预估风险对提高乳腺癌患者的存活率关系重大。英国研究人员最近通过一种新的测序技术发现了110个与乳腺癌风险有关的基因,可望为通过基因检测来预估乳腺癌风险铺平道路。

伦敦癌症研究所的研究人员在新一期英国《自然·通讯》杂志上报告说,他们通过新测序技术分析了基因组上被认为与乳腺癌相关的63个区域的图谱,并在其中的33个区域内发现了110个可能会增加乳腺癌患病风险的基因。

寻找与患病风险相关的基因并不简单,因为DNA片段会与基因组中完全不相关的片段发生相互作用,产生一种被称为“DNA环”的结构,干扰基因识别。为此研究人员开发了一种被称为Capture Hi-C的测序技术,分析乳腺癌高危区域的图谱。

新确认的110个基因绝大多数在此前并未被认为与乳腺癌风险相关。此外,通过参照病人资料,研究人员发现其中新确认的32个基因与雌激素受体阳性乳腺癌患者的存活率相关。他们表示要进一步研究新确认的基因,以断定它们在乳腺癌中起何种程度的作用。

伦敦癌症研究所遗传流行病学组组长奥利维娅·弗莱彻表示:“发现这些新基因将有助于我们更详细地了解乳腺癌风险的遗传学机理,最终我们的研究可以为通过基因检测预估测乳腺癌风险,或为新型靶向治疗铺平道路。”

原始出处:

Joseph S. Baxter,et al.Capture Hi-C identifies putative target genes at 33 breast cancer risk loci.Nat Commun.12 March 2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061722, encodeId=c9dd2061e2259, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jun 26 22:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770294, encodeId=2b961e70294b0, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Jun 27 01:29:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882915, encodeId=b1161882915db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 28 06:29:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087307, encodeId=6111208e307c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 01 22:29:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302715, encodeId=574d302e15f9, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Apr 04 17:05:52 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302331, encodeId=761330233141, content=期待进一步研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/24/965105b95fe53b6329b522fe372907a2.jpg, createdBy=34621617558, createdName=zanzaifeng, createdTime=Tue Apr 03 08:18:33 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-06-26 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061722, encodeId=c9dd2061e2259, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jun 26 22:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770294, encodeId=2b961e70294b0, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Jun 27 01:29:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882915, encodeId=b1161882915db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 28 06:29:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087307, encodeId=6111208e307c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 01 22:29:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302715, encodeId=574d302e15f9, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Apr 04 17:05:52 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302331, encodeId=761330233141, content=期待进一步研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/24/965105b95fe53b6329b522fe372907a2.jpg, createdBy=34621617558, createdName=zanzaifeng, createdTime=Tue Apr 03 08:18:33 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061722, encodeId=c9dd2061e2259, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jun 26 22:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770294, encodeId=2b961e70294b0, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Jun 27 01:29:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882915, encodeId=b1161882915db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 28 06:29:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087307, encodeId=6111208e307c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 01 22:29:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302715, encodeId=574d302e15f9, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Apr 04 17:05:52 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302331, encodeId=761330233141, content=期待进一步研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/24/965105b95fe53b6329b522fe372907a2.jpg, createdBy=34621617558, createdName=zanzaifeng, createdTime=Tue Apr 03 08:18:33 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-08-28 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061722, encodeId=c9dd2061e2259, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jun 26 22:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770294, encodeId=2b961e70294b0, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Jun 27 01:29:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882915, encodeId=b1161882915db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 28 06:29:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087307, encodeId=6111208e307c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 01 22:29:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302715, encodeId=574d302e15f9, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Apr 04 17:05:52 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302331, encodeId=761330233141, content=期待进一步研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/24/965105b95fe53b6329b522fe372907a2.jpg, createdBy=34621617558, createdName=zanzaifeng, createdTime=Tue Apr 03 08:18:33 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2019-03-01 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061722, encodeId=c9dd2061e2259, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jun 26 22:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770294, encodeId=2b961e70294b0, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Jun 27 01:29:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882915, encodeId=b1161882915db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 28 06:29:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087307, encodeId=6111208e307c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 01 22:29:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302715, encodeId=574d302e15f9, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Apr 04 17:05:52 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302331, encodeId=761330233141, content=期待进一步研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/24/965105b95fe53b6329b522fe372907a2.jpg, createdBy=34621617558, createdName=zanzaifeng, createdTime=Tue Apr 03 08:18:33 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-04 wxl882001

    学习一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2061722, encodeId=c9dd2061e2259, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jun 26 22:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770294, encodeId=2b961e70294b0, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Jun 27 01:29:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882915, encodeId=b1161882915db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 28 06:29:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087307, encodeId=6111208e307c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 01 22:29:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302715, encodeId=574d302e15f9, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Apr 04 17:05:52 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302331, encodeId=761330233141, content=期待进一步研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/24/965105b95fe53b6329b522fe372907a2.jpg, createdBy=34621617558, createdName=zanzaifeng, createdTime=Tue Apr 03 08:18:33 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-03 zanzaifeng

    期待进一步研究进展

    0

相关资讯

JCO:仅有骨转移的乳腺癌患者临床结局有何不同?

目前仅有骨转移(BO)的乳腺癌患者(MBC)的比例和结局尚未很好描述其特征。而近日在著名肿瘤学杂志JCO上发表的一篇文章则试图描述BO的MBC患者在临床试验中的不同结局,并探讨研究者与盲法独立中央评估之间是否存在放射学读数差异。

Sci Tran Med:科学家发现治疗乳腺癌失败的又一大因素

肥胖--已知会降低几种癌症的存活率,可能解释了血管生成抑制剂在治疗乳腺癌方面的无效性。一个研究小组首次发现,肥胖和肥胖相关的分子因素似乎在乳腺癌患者和两种小鼠模型中诱导了对抗血管生成治疗的抗性。 他们在“科学转化医学”中的报告还详细介绍了与这种耐药相关的特定肥胖相关因素,并概述了可能会克服它的潜在治疗策略。

JCO:HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析

GeparQuinto Ⅲ期临床试验发现与曲妥珠单抗相比,拉帕替尼联合标准蒽环类-紫衫类化疗治疗HER2阳性乳腺癌病理完全缓解(pCR;pT0 ypN0)率更低。JCO近期发表了一篇文章,报道了长期随访结果。

乳腺癌须“分类而治”,贫困地区女性健康项目在沪启动

目前,我国乳腺癌的发病率呈急速增长态势,我国女性乳腺癌发病率为42.55/10万人,严重威胁女性健康。其中,每年偏远贫困地区女性乳腺癌发病约9.8万,占农村全部女性乳腺癌发病的14.11%。据中国抗癌协会乳腺癌专业委员会主任委员任国胜教授介绍,从病理上来看,乳腺癌包含四种分子亚型:Luminal A型,Luminal B型,HER2阳性,以及三阴性乳腺癌,确诊乳腺癌的患者应当及早进行分子病理检测

Nat Commun:ctDNA检测有助于预测药物对乳腺癌患者的有效性

循环肿瘤DNA(ctDNA)是肿瘤活检的一种替代指标,可用于评估驱动基因突变,如肺癌中的EGFR,还可以评估多发转移患者的克隆演变。目前多是用于癌症早期筛查研究。最新一项研究发现,ctDNA检测可以预测激素受体阳性、her2阴性乳腺癌患者对CDK4/6抑制剂palbociclib 的反应。

Adv Funct Mater:肿瘤选择性仿生纳米粒可抑制乳腺癌原位瘤生长及肺部转移

乳腺癌严重危害女性健康,转移是导致乳腺癌患者死亡的主要原因。目前传统化疗依然是临床治疗乳腺癌原发瘤及转移灶的主要手段。但由于化疗药物缺乏针对肿瘤细胞的靶向性,导致严重毒副作用,极大限制了化疗的临床应用。